Background: Cigarette smoking induces cytochrome P450 1A2, which metabolizes clopidogrel to its active form. The pharmacodynamic effect of smoking on platelet inhibition in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention (PCI) is unknown.
Background: Cigarette smoking induces cytochrome P450 1A2, which metabolizes clopidogrel to its active form. The pharmacodynamic effect of smoking on platelet inhibition in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention (PCI) is unknown. methods: Platelet reactivity was assessed in 5,427 patients of the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial. VerifyNow P2Y12 Reaction Units (PRU) were obtained at 12-24 hours (baseline), 30 days, and 6 months after PCI. Patients were stratified by smoking status. Patients with high OTR (≥230 PRU) were randomized to clopidogrel 75 mg or 150 mg daily.
results: At baseline, smokers (n=971) had lower PRU than non-smokers (n=4,456) (183±91 PRU vs 207±93 PRU; p<0.001), and were less likely to have high OTR (31.9% vs 42.1%; p<0.001). In patients with high OTR randomized to clopidogrel 75 mg, smokers had significantly lower PRU than non-smokers over time. However, in patients on clopidogrel 150 mg, PRU was not significantly different between smokers and non-smokers over time.
Smokers on clopidogrel 75 mg were also less likely to have high OTR, but no difference was observed in those on clopidogrel 150 mg (Table) . Tests demonstrated an interaction between smoking and dosing strategy at 30 days (p=0.007) and 6 months (p=0.098).
conclusion: In GRAVITAS, smokers had greater platelet inhibition on clopidogrel 75 mg, but this difference was eliminated with the 150 mg dose. Results reported as PRU mean ± standard deviation. P-value for the comparison of smokers and non-smokers at each time point. *Defined as smoking within the past 7 days.
